BACKGROUND: The incidence of venous thromboembolic events (VTE) after resection of thoracic malignancies can reach 15%, but prophylaxis guidelines are yet to be established. We aimed to survey Canadian practitioners regarding perioperative risk factors for VTE, impact of those factors on extended prophylaxis selection, type of preferred prophylaxis, and timing of initiation and duration of thromboprophylaxis. METHODS: A modified Delphi survey was undertaken over three rounds with thoracic surgeons, thoracic anesthesiologists and thrombosis experts across Canada. Participants were asked to rate each parameter on a ten-point scale. Agreement was determined a priori as an item reaching a coefficient of variation of ≤30% (0.3), with the item then discontinued from later rounds. RESULTS: In total, 72, 57 and 50 respondents participated in three consecutive rounds, respectively. Consensus was reached on previous VTE, age, cancer diagnosis, thrombophilia, poor mobilization, extended resections, and pre-operative chemotherapy as risk factors. Consensus on risk factors impacting extended prophylaxis decisions was achieved on cancer diagnosis, obesity, previous VTE and poor mobilization. With respect to perioperative prophylaxis, once daily low-molecular-weight heparin (LMWH) was the only parameter that demonstrated agreement as a common practice pattern. No agreement was achieved regarding the role of mechanical prophylaxis, unfractionated heparin (UFH) or timing of initiation of peri-operative treatment. VTE prophylaxis until discharge reached agreement but there was substantial variability regarding the role of extended prophylaxis. CONCLUSIONS: There is agreement between Canadian clinicians treating patients with thoracic malignancies regarding most risk factors for VTE, but there is no agreement on timing of initiation of prophylaxis, the agents used or factors mandating usage of extended prophylaxis.
BACKGROUND: The incidence of venous thromboembolic events (VTE) after resection of thoracic malignancies can reach 15%, but prophylaxis guidelines are yet to be established. We aimed to survey Canadian practitioners regarding perioperative risk factors for VTE, impact of those factors on extended prophylaxis selection, type of preferred prophylaxis, and timing of initiation and duration of thromboprophylaxis. METHODS: A modified Delphi survey was undertaken over three rounds with thoracic surgeons, thoracic anesthesiologists and thrombosis experts across Canada. Participants were asked to rate each parameter on a ten-point scale. Agreement was determined a priori as an item reaching a coefficient of variation of ≤30% (0.3), with the item then discontinued from later rounds. RESULTS: In total, 72, 57 and 50 respondents participated in three consecutive rounds, respectively. Consensus was reached on previous VTE, age, cancer diagnosis, thrombophilia, poor mobilization, extended resections, and pre-operative chemotherapy as risk factors. Consensus on risk factors impacting extended prophylaxis decisions was achieved on cancer diagnosis, obesity, previous VTE and poor mobilization. With respect to perioperative prophylaxis, once daily low-molecular-weight heparin (LMWH) was the only parameter that demonstrated agreement as a common practice pattern. No agreement was achieved regarding the role of mechanical prophylaxis, unfractionated heparin (UFH) or timing of initiation of peri-operative treatment. VTE prophylaxis until discharge reached agreement but there was substantial variability regarding the role of extended prophylaxis. CONCLUSIONS: There is agreement between Canadian clinicians treating patients with thoracic malignancies regarding most risk factors for VTE, but there is no agreement on timing of initiation of prophylaxis, the agents used or factors mandating usage of extended prophylaxis.
Entities:
Keywords:
Blood; coagulation/anticoagulation; esophageal surgery operations; lung cancer surgery; pulmonary embolism (PE); surgery complications
Authors: Brittany A Zwischenberger; Ching-Wei D Tzeng; Nicholas D Ward; Joseph B Zwischenberger; Jeremiah T Martin Journal: Ann Thorac Surg Date: 2015-09-26 Impact factor: 4.330
Authors: Giancarlo Agnelli; Giorgio Bolis; Lorenzo Capussotti; Roberto Mario Scarpa; Francesco Tonelli; Erminio Bonizzoni; Marco Moia; Fabio Parazzini; Romina Rossi; Francesco Sonaglia; Bettina Valarani; Carlo Bianchini; Gualberto Gussoni Journal: Ann Surg Date: 2006-01 Impact factor: 12.969
Authors: David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Thomas D Christensen; Henrik Vad; Søren Pedersen; Anne-Mette Hvas; Robin Wotton; Babu Naidu; Torben B Larsen Journal: Ann Thorac Surg Date: 2013-12-21 Impact factor: 4.330
Authors: David P Mason; Mohammad A Quader; Eugene H Blackstone; Jeevanantham Rajeswaran; Malcolm M DeCamp; Sudish C Murthy; Angela K Quader; Thomas W Rice Journal: J Thorac Cardiovasc Surg Date: 2006-03 Impact factor: 5.209
Authors: John Agzarian; Waël C Hanna; Laura Schneider; Colin Schieman; Christian J Finley; Yury Peysakhovich; Terri Schnurr; Dennis Nguyen-Do; Lori-Ann Linkins; James Douketis; Mark Crowther; Marc De Perrot; Thomas K Waddell; Yaron Shargall Journal: J Thorac Cardiovasc Surg Date: 2015-11-26 Impact factor: 5.209
Authors: Kristen McAlpine; Rodney Breau; Marc Carrier; Philippe Violette; Christopher Knee; Ilias Cagiannos; Christopher Morash; Luke Lavallée Journal: Can J Surg Date: 2020-11-30 Impact factor: 2.089